Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 12/20 | 0.53 |
| ▸ | GSK3B | P49841 | 11/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 11/20 | 0.53 |
| ▸ | SRC | P12931 | 8/20 | 0.53 |
| ▸ | PLK4 | O00444 | 5/20 | 0.49 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.47 |
| ▸ | PAK4 | O96013 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174749 | 0.85 | AURKA (0.53) | AURKAGSK3BAURKBSRCPLK4 | |
| SCHEMBL174267 | 0.79 | PLK4 (0.47) | AURKAAURKBPLK4PAK4 | |
| SCHEMBL174456 | 0.78 | PLK4 (0.59) | AURKAPLK4PAK4 | |
| SCHEMBL173973 | 0.77 | AURKA (0.59) | AURKAGSK3BAURKBSRCPLK4 | |
| SCHEMBL173716 | 0.71 | PLK4 (0.58) | AURKAAURKBPLK4PAK4 | |
| SCHEMBL25875763 | 0.70 | PLK4 (0.63) | AURKAGSK3BAURKBSRCPLK4 | |
| SCHEMBL12430446 | 0.70 | AURKA (1.00) | AURKAGSK3BAURKBSRCAURKC | |
| SCHEMBL12510494 | 0.70 | AURKA (0.89) | AURKAGSK3BAURKBSRCAURKC | |
| SCHEMBL174770 | 0.69 | PLK4 (0.48) | AURKAGSK3BAURKBSRCPLK4 | |
| SCHEMBL12430592 | 0.69 | AURKA (0.87) | AURKAGSK3BAURKBSRCAURKC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-14 | — | — | US | disclosed |
| EP-2611809-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030924-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, JAK1 | AURKA 174/4885GSK3B 353/4885AURKB 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.